Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients

Journal of Clinical Gastroenterology

Volumn 49, Issue 3, 2015, Pages 235-241

  Fernandes, Flavia F ^a,b   Ferraz, Maria L ^c,e   Andrade, Luiz E ^e   Dellavance, Alessandra ^f   Terra, Carlos ^a   Pereira, Gustavo ^b   Pereira, João L ^b   Campos, Frederico ^a,b   Figueiredo, Fátima ^a,d   Perez, Renata M ^a,d,e  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Bonsucesso Federal Hospital   (Brazil)

^c D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f Fleury   (Brazil)

Author keywords

ELF score; Hepatitis C; Liver biopsy; Liver fibrosis; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HYALURONIC ACID; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE; TIMP1 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOMATION; BIOPSY NEEDLE; CHRONIC PATIENT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISPOSABLE EQUIPMENT; ELASTOGRAPH; ELASTOGRAPHY; ENHANCED LIVER FIBROSIS; FEMALE; GOLD STANDARD; HEPATITIS C; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS BIOPSY; PORTAL VEIN; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REFUSAL TO PARTICIPATE; SENSIBILITY; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY; AGED; AREA UNDER THE CURVE; BIOPSY; BLOOD; COMPARATIVE STUDY; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDY; HEPATITIS C, CHRONIC; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; RISK FACTOR; VIROLOGY;

ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ROC CURVE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84922716791     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000128     Document Type: Article

References (44)

1. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449-1457.
2. Strader DB WT, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39: 1147-1171.
3. Mehta SH, Lau B, Afdhal NH, et al. Exceeding the limits of liver histology marker. J Hepatol. 2009;50:36-41.
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
5. Casterá L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography versus liver biopsy? Liver Int. 2011;31:13-17.
6. Bedossa P. Assessment of hepatitis C:non-invasive fibrosis markers and/or liver biopsy. Liver Int. 2009;suppl 1:19-22.
7. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239-244.
8. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986;1:523-525.
9. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618.
10. Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol. 1996;25:649-654.
11. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther. 2009;30:557-576.
12. Casterá L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142: 1293-1302.
13. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2004;38:518-526.
14. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferaseto-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-921.
15. Forns X, Ampurdanès S, Llovet J, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-992.
16. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV Infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007; 46:32-36.
17. Lok A, Ghany M, Goodman Z, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C Cohort. Hepatology. 2005;4:282-292.
18. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075.
19. Calès P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373-1381.
20. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-1873.
21. Lédinghen V, Vergniol J. Transient elastography (FibroScan). Gastroentérol Clin Bio. 2008;32:58-67.
22. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a metaanalysis. Gastroenterology. 2008;134:960-974.
23. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828-835.
24. Rosenberg W, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704-1713.
25. George J, Tsutsumi M, Takase S. Expression of hyaluronic acid in Nnitrosodimethylamine induced hepatic fibrosis in rats. Int J Biochem Cell Biol. 2004;36:307-319.
26. J.Parkes J, Guha N, Roderick P, et al. Enhanced liver fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Vir Hepatitis. 2011;18:23-31.
27. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the european liver fibrosis panel and exploring simple markers. Hepatology. 2008;47:455-460.
28. Cobbold JFL, Crossey M, Colman P, et al. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Vir Hepatitis. 2010;17:537-545.
29. Friedrich-Rust M, Rosenberg W, Parkes P, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010;10:103.
30. Crespo G, Fernández-Varo G, Mariño Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol. 2012;57:281-287.
31. Wahl K, Rosenberg W, Vaske B, et al. Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS ONE. 2012; 7:e51906.
32. Kim BK, Kim HS, Park JY, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS ONE. 2012;7:e41964.
33. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008;48:1549-1557.
34. Guéchot J, Trocmé C, Renversez JC, et al. Independent validation of the enhanced liver fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med. 2012;50:693-699.
35. Martinez SM, Fernández-Varo G, Gonzalez P, et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:138-148.
36. Zarski JP, Guechot J, Zafrani E, et al. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS ONE. 2013;8:e59088.
37. Yoo E, Kim BK, Kim SU, et al. Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. Liver Int. 2013;33:706-713.
38. Lichtinghagen R, Pietsch D, Bantel H, et al. The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013;59:236-242.
39. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289-293.
40. Casterá L, Foucher J, Le Bail B, et al. Prospective comparison of transient elastography, Fibrotest,APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343-350.
41. Obuchowski N. Estimating and comparing diagnostic tests' accuracy when the gold standard is not binary. Acad Radiol. 2005;12:1198-1204.
42. Lambert J, Penaranda G, Bedossa P, et al. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem. 2008;54: 1372-1378.
43. Catanzaro R, Arona S, Sapienza C, et al. Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int. 2013;12:500-507.
44. Sebastiani G, Casterá L, Galfon P, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 2011;34: 1202-1216.